Thomas K. Equels, CEO, President, and Director of AIM ImmunoTech Inc., filed a statement of changes in beneficial ownership on October 26, 2026, disclosing an open-market purchase of common stock on October 23, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, who serves as CEO, President, and Director of AIM ImmunoTech Inc.
  • Transaction: Purchase (code P) of 31,675 shares of common stock on October 23, 2026.
  • Price paid: $0.16 per share, according to the filing.
  • Resulting ownership: Equels directly holds 189,747 shares of common stock following the transaction.
  • No derivative securities: No derivative security transactions were reported in this filing.

Equels Adds to Direct Common Stock Position in October 2026

According to the filing, Thomas K. Equels acquired 31,675 shares of AIM ImmunoTech Inc. common stock at a price of $0.16 per share on October 23, 2026. The transaction was coded as a purchase (P) under the applicable reporting instructions, and ownership of the acquired shares is held directly by Equels. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan.

AIM ImmunoTech Inc. trades on NYSE American under the ticker symbol AIM, as listed in the filing's issuer field. Following the reported purchase, Equels' direct beneficial ownership in the company's common stock stood at 189,747 shares, per the filing. No transactions involving derivative securities, such as options or warrants, were reported in Table II of the disclosure. The filing was signed by Thomas K. Equels and dated October 26, 2026.

What Was Disclosed

The filing disclosed a single open-market purchase by AIM ImmunoTech's CEO and President, Thomas K. Equels, of 31,675 common shares at $0.16 per share on October 23, 2026, bringing his total direct beneficial ownership to 189,747 shares.